Human acellular amniotic membrane is adopted to treat venous ulcers
- Authors:
- Zhoupeng Wu
- Xiaoyan Liu
- Ding Yuan
- Jichun Zhao
View Affiliations
Affiliations: Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
- Published online on: June 20, 2018 https://doi.org/10.3892/etm.2018.6331
-
Pages:
1285-1289
-
Copyright: © Wu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Venous lower limb ulcers are very common and affect ~1% of the general population. The human acellular amniotic membrane (HAAM), which is isolated from the amniotic membrane (AM) via excluding the majority of cellular components, has lower antigenicity than the AM. The aim of the present study was to evaluate the effectiveness and safety of the HAAM, adopted to treat venous ulcers (VUs) of the lower extremities. The HAMM was isolated from the AM by the Stem Cells and Tissue Engineering laboratory at the West China Hospital of Sichuan University (Chengdu, China). HAMMs were grafted onto VUs in 4 patients, with follow‑up evaluations performed on the 3rd day and at the end of the 1st, 2nd and 3rd week, and 2nd, 3rd and 6th month after the HAAMs were applied. The size and depth of the VU (determined based on whether the depth of VU reaches the tibial plane), the proportion of granulation tissue (whether >50%) and the degree of secretion (measured by asessing the degree of satuation in the outer gauze) and infection (assessed qualitatively via the appearance of purulence or peripheral swelling) were assessed. Pain score was monitored at the same intervals using a visual analog scale. Complete epithelialization (healed tissue) occurred in 2 cases: The first at the end of the 3rd week and the second, at the 2nd month following HAAM induction. In one of the remaining cases, ulcer size was reduced by >60%; however the ulcer size of the remaining case only reduced by <20%. Overall, the size of ulcer in cases 1, 2, 3 and 4 decreased to 1.2x1.1 and 1.4x0.4 cm, 1.3x1.8 and 2.3x1.4, respectively, with evident decreases in ulcer depth. The proportion of granulation tissue in each case was >50%. Furthermore, purulence and secretion completely disappeared in all 4 cases. Additionally, the medical cost of HAAM treatment is substantially lower than that of AM treatment, skin autografts and biomaterial transplantation, thus alleviating the patients' financial burden. These findings suggest that HAMM was highly effective in treating VUs in patients.
View References
|
1
|
Patel NP, Labropoulos N and Pappas PJ:
Current management of venous ulceration. Plast Reconstr Surg. 117
Suppl:S254–S260. 2006. View Article : Google Scholar
|
|
2
|
Lo V and Pope E: Amniotic membrane use in
dermatology. Int J Dermatol. 48:935–940. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Litwiniuk M, Bikowska B, Niderla-Bielińska
J, Jóźwiak J, Kamiński A, Skopiński P and Grzela T: Potential role
of metalloproteinase inhibitors from radiation sterilized amnion
dressings in the healing of venous leg ulcers. Mol Med Rep.
6:723–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mermet I, Pottier N, Sainthillier JM,
Malugani C, Cairey-Remonnay S, Maddens S, Riethmuller D, Tiberghien
P, Humbert P and Aubin F: Use of amniotic membrane transplantation
in the treatment of venous leg ulcers. Wound Repair Regen.
15:459–464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh R, Chouhan US, Purohit S, Gupta P,
Kumar P, Kumar A, Chacharkar MP, Kachhawa D and Ghiya BC: Radiation
processed amniotic membranes in the treatment of non-healing ulcers
of different etiologies. Cell Tissue Bank. 5:129–134. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gutiérrez-Moreno S, Alsina-Gibert M,
Sampietro-Colom L, Pedregosa-Fauste S and Ayala-Blanco P:
Cost-benefit analysis of amniotic membrane transplantation for
venous ulcers of the legs that are refractory to conventional
treatment. Actas Dermosifiliogr. 102:284–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo JC, Li XQ and Yang ZM: Preparation of
human acellular amniotic membrane and its cytocompatibility and
biocompatibility. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.
18:108–111. 2004.PubMed/NCBI
|
|
8
|
Sawhney CP: Amniotic membrane as a
biological dressing in the management of burns. Burns. 15:339–342.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beele H, de la Brassine M, Lambert J, Suys
E, De Cuyper C, Decroix J, Boyden B, Tobback L, Hulstaert F, De
Schepper S, et al: A prospective multicenter study of the efficacy
and tolerability of cryopreserved allogenic human keratinocytes to
treat venous leg ulcers. Int J Low Extrem Wounds. 4:225–233. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bailo M, Soncini M, Vertua E, Signoroni
PB, Sanzone S, Lombardi G, Arienti D, Calamani F, Zatti D, Paul P,
et al: Engraftment potential of human amnion and chorion cells
derived from term placenta. Transplantation. 78:1439–1448. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Walker AB, Cooney DR and Allen JE: Use of
fresh amnion as a burn dressing. J Pediatr Surg. 12:391–395. 1977.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ganatra MA: Amniotic membrane in surgery.
J Pak Med Assoc. 53:29–32. 2003.PubMed/NCBI
|
|
13
|
Kubo M, Sonoda Y, Muramatsu R and Usui M:
Immunogenicity of human amniotic membrane in experimental
xenotransplantation. Invest Ophthalmol Vis Sci. 42:1539–1546.
2001.PubMed/NCBI
|
